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Abstract
Early health technology assessment (HTA), which includes all methods used to inform
industry and other stakeholders about the potential value of new medical products in
development, including methods to quantify and manage uncertainty, has seen many
applications in recent years. However, it is still unclear how such early value assessments
can be integrated into the technology innovation process. This commentary contributes
to the discussion on the purposes early HTA can serve. Similarities and differences in the
perspectives of five stakeholders (i.e., the hospital, the patient, the assessor, the medical
device industry, and the policy maker) on the purpose, value, and potential challenges of
early HTA are described. All five stakeholders agreed that integrating early HTA in the
innovation process has the possibility to shape and refine an innovation, and inform
research and development decisions. The early assessment, using a variety of
methodologies, can provide insights that are relevant for all stakeholders but several
challenges, for example, feasibility and responsibility, need to be addressed before early
HTA can become standard practice. For early evaluations to be successful, all relevant
stakeholders including patients need to be involved. Also, nimble, flexible assessment
methods are needed that fit the dynamics of medical technology. Best practices should
be shared to optimize both the innovation process and the methods to perform an early
value assessment.
Introduction
Innovative healthcare technologies are constantly being developed and marketed with the
claim that they promote value in healthcare. Whether a technology, which encompasses every-
thing from new medical devices to organizational services, indeed has potential value for the
patient and society can be evaluated with a health technology assessment (HTA). According to
the new definition of HTA recently released by an international joint task group co-led by the
International Network of Agencies for Health Technology Assessment (INAHTA) and Health
Technology Assessment International (HTAi), HTA is a multidisciplinary process that uses
explicit methods to determine the value of a health technology at different points in its lifecycle
(1). Extending the traditional HTA that informs coverage/reimbursement decisions, early HTA
informs early research, development, and investment decisions. This allows the potential value
of a new health technology to be determined at an early stage of its development (2).
As the process of determining the (added) value of a technology during its development
and pilot phases may optimize its market pathway (3), HTA is increasingly being applied in
earlier stages of its development process (4). IJzerman et al. define this “early HTA” as “all
methods used to inform industry and other stakeholders about the potential value of new
medical products in development, including methods to quantify and manage uncertainty”
(4). While there is no strict distinction between “traditional” and “early” HTA, the authors
emphasize that in early HTA the innovation is still under development, noting that “the def-
inition includes early HTA of medical products just before and also at the early stages of clin-
ical use, while accepting that product development can continue after regulatory approval” (4).
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In early HTA, traditional HTA methodology is commonly
applied, but with a different timing and purpose (4–6). It is
now used to explore the potential value of the technology in its
intended context when there still is insufficient evidence on the
technology. Early HTA asks the following questions: Does the
innovation meet an unmet need? How may the technology impact
the designated context? What are potential barriers for and facil-
itators of its use? What needs to be researched when and how?
How can the value of the technology be optimized after imple-
mentation? Early assessment allows researchers and developers
to proactively address uncertainty, anticipate the extent of accep-
tance, and potentially improve the efficiency of evaluation
research and the development of new technologies—shifting the
goal of HTA from summative to formative, and from retrospective
to prospective, to guide further research and development (7;8).
Recent years have seen many applications and methodological
studies of early HTA (4;5;7;9–13). However, it remains unclear
how early HTA can be made to fit in with day-to-day healthcare
decision making and how it can be integrated into the innovation
process. What does early HTA add to current practices and what
are its advantages and challenges? The aim of this commentary is
to contribute to the discussion on the purposes an early HTA can
serve by providing personal reflections from different perspec-
tives: the hospital, the patient, the assessor, the medical device
industry, and the policy maker.
Views on early HTA from different perspectives
The hospital—Laura Sampietro-Colom
Hospitals are one of the main entry doors of health technologies,
but they are also the place where innovation usually flourishes in
pursuit of solutions to health and healthcare needs not solved in
every-day clinical practice. While sometimes the ideas brought by
healthcare professionals seem at first very interesting; only very
few of them reach the market. This is due to several reasons,
but one of the most important is the lack of a systematic analysis
about the potential value of the technology in the early stages of
development. Clinicians are usually not familiar with the type of
information that is required for making adoption decisions, nei-
ther do they know how to analyze whether the product has a
chance of properly solving the identified problem (considering
all stakeholder perspectives). HTA brings the scientific knowledge
and the accumulated life experience on how technologies should
be valued, and how they actually are valued by those who will
decide on their incorporation and coverage in health systems.
By applying early HTA in hospitals, developers can demonstrate
the value of their prototypes. Moreover, hospitals can become a
perfect lab for start-ups/spin-offs to co-develop technologies
and to test their value. An example of this is the evaluation of soft-
ware (integrated in magnetic resonance technology) developed
within a hospital to visualize existing conductivity channels in
the heart tissue after a massive myocardial infarction (14).
Nevertheless, there are challenges to carry out early HTA that
need to be overcome at the hospital level. Still many healthcare
professionals are not aware of what HTA is, and those who
know it see HTA far from their clinical practice, like something
that happens on a macro level and cannot help them in advancing
the development of their technologies. One solution is to apply
existing expertise on hospital-based HTA in hospitals.
Unfortunately, although there is an increasing interest to adopt
hospital-based HTA (15), as exemplified by countries like China
and Poland and some European countries, still most university
hospitals lack this expertise.
The patient—Dominique Hamerlijnck
Involving patient experts and patient organizations early in the
development process of new innovations increases the possibility
that innovations will capture the values that are important to
patients. To achieve this, technology developers and researchers
need to work closely together with patient experts and patient
organizations, co-creating from the very beginning. This is also
emphasized by Patients Active in Research and Dialogues for
and Improved Generation of Medicines (PARADIGM), a
European initiative and public-private partnership co-led by the
European Patients’ Forum (EPF) and the European Federation
of Pharmaceutical Industries and Associations (EFPIA).
PARADIGM develops tools to achieve the co-creation process,
especially with patients. All stakeholders, including patients,
should be invited to join in an early dialogue. Based on the
good evidence input from all stakeholders, joint inquiry can
help formulate the right questions and perspective. Where do
the needs and requirements of all participants (e.g., patients, sci-
entists, companies, physicians, researchers) meet and which new
technologies will benefit all? What are viable options for improve-
ment? How can the technologies, whether medicines or devices,
create a positive result for all? What are the relevant questions
to ask? And, most importantly from the patient perspective:
What outcomes merit improvement? How can these be measured
in a fit-for-purpose way? How can we attain content and con-
struct validity and reliability, and measures sufficiently sensitive
to detect meaningful within-group and within-patient change
(16)? By listening to patients and translating their views, wishes,
and needs into questions that are germane for all stakeholders,
we can ensure that the health outcomes will be relevant for the
patients targeted.
Early HTA can be useful to monitor whether stakeholders
agree on the chosen approach, whether advice and scientific evi-
dence is obtained from all, to record progress, and verify whether
each step reflects the various ideas and desired outcomes and how
this can be improved if needed. Finally, it is recommended to
obtain the regulator’s perspective on the plans and next steps.
This will help save money and effort in both the research and
health budgets.
The assessor—Øyvind Melien
While in the inception of health technologies there is a tendency
to focus on the launch phase, it is crucial to extend the scope to
the innovation’s life cycle for the benefit of the patients. Research
and development, introduction, follow-up, improvement, or dis-
investment of health technologies all rely on continuous informa-
tion and evaluation with reference to relevance, needs, efficiency,
safety, and economic viability. In this chain of events, early HTA
may fill a gap by facilitating the interaction among and informa-
tion dissemination to relevant stakeholders such as patient repre-
sentatives, health professionals, research and development,
industry, authorities, and procurement organizations. A major
driving force and consideration in modern medicine is to pro-
mote targeted interventions in accordance with the concepts of
personalized medicine to address the needs of both the individual
patient and the healthcare system in general. Early HTA may then
support the development of such targeted health interventions by
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capturing, evaluating, and sharing valuable data at an early stage
to steer the research and development processes into the desired
direction. That way it may help improve the life-cycle perspective
of novel health technologies from their inception and inform
stakeholder dialogues early in the process.
The medical device industry—Markus Siebert
In medical device industry, early HTA is first and foremost an
internal process that needs to be established within the company.
Because it is so different from traditional HTA, we would prefer to
call the approach an “early value assessment.” It involves a multi-
disciplinary venture initiated at the inception phase of a technol-
ogy or during the due diligence process of a potential acquisition.
Input from Pricing Health Economics & Reimbursement, Sales &
Marketing, Regulatory Affairs, and Clinical Affairs is gathered,
incorporating the voices of the relevant geographies. By factoring
in its values for payers and/or society early on, the value proposi-
tion and price of a technology can be determined in such a way as
to improve its acceptability and adoption rate. If this approach is
not followed, this may result in an innovation that is not needed
or brought to market at costs (and hence prices) that are unreal-
istic in the eyes of both payers and customers—ultimately imped-
ing market access.
Accordingly, an early value assessment should be a standard
component of any pre-market strategy for medical device innova-
tions that are “disruptive” from a technological or financial per-
spective, at the stage of technology scanning and product
conception. For this approach to be successful, robust internal
processes need to be established, starting with a decision-making
tool that helps determine when an early HTA is needed. Outreach
initiatives, comprising early dialogues, need to be launched target-
ing the most important external stakeholders—payers, hospitals,
and where appropriate, patients—to assess their needs and will-
ingness and ability to pay. The technology in question needs to
be positioned against the current and possible future realities of
coverage, reimbursement, and cost-effectiveness in major geogra-
phies of the world.
The results from the early HTA need to inform product
design, clinical and economic evidence strategies, and price set-
ting. Although we can draw from existing academic expertise in
HTA and hospital-based HTA, it is fair to say that early value
assessment also requires new tools and skills. It needs to move
much faster than traditional HTA, simulate scenarios, elicit multi-
stakeholder input through early dialogues, and ultimately com-
bine the rigor of science with pragmatic advice to industry.
The policy maker—Payam Abrishami
New medical and data-driven technologies are often developed
and introduced in the healthcare system in a highly dynamic pro-
cess. From the policy maker perspective, two characteristics of this
process signify the importance of early HTA: the diversity of
stakeholders involved and a traditional separation of development
and evaluation in the innovation process.
Decisions on the development and introduction of novel tech-
nologies are typically made by diverse stakeholders in decentral-
ized arrangements (i.e., at the discretion of local stakeholders in
advance or absence of explicit national assessments). Second,
new technology is often introduced in a sequential fashion:
from ideation to prototype design, to proof of principle, market
entry, financing, acquisition, spread, and implementation. Since
these tasks are distinctive in terms of execution and immediate
information needs, a division of labor in the introduction of inno-
vations seems inevitable. While the responsibilities are dispersed,
the purpose is fairly shared: providing value for the patient and
value for society (16). Early HTA can be seen as an (as yet miss-
ing) “link” between the different loci and foci of technological
innovations and the desirable value for patient and society.
Early HTA is also congruent with the current policies of regula-
tory agencies and health authorities to favor promising innova-
tions without imposing strict actuarial controls or top-down
restrictions, and is well-attuned to the decentralized, market-
oriented processes in introducing medical innovations.
Accordingly, early HTA should have an iterative nature, partic-
ularly for expensive technologies or innovations with a broad
application field and a potential for large-scale, drastic changes
such as telecare, artificial intelligence, gene editing. It helps stake-
holders to:
• clarify the innovation’s value proposition, with stakeholders col-
laboratively identifying claims of benefit of a new medical tech-
nology and clarifying its place in the entire care pathway, and
• establish and sustain “innovating-in-research”/managed entry
schemes, where early HTA enhances mutual understanding
and alignment between regulatory and HTA agencies, and
among innovators, medical professionals, and health insurers/
payers on what kind of evidence is relevant to demonstrate
the claimed (added) benefits. This involves agreeing on the
design of clinical and cost-effectiveness studies early on, includ-
ing the target population, comparator, relevant outcome mea-
sure(s), follow-up period, and, notably, consideration of all
relevant patient perspectives. In so doing, early HTA can pro-
mote a shift from a first-innovate-then-evaluate approach
toward an iterative innovate-and-evaluate approach.
Implications and recommendations
From the perspectives presented above, we can derive that early
HTA can help to shape and develop health technology, inform
early research and development decisions, and guide evidence
generation. Using diverse, systematic methodologies, early assess-
ments can provide insights that are relevant for developers and
decision makers. Implementation of an innovation may fail
when key players have different perspectives as to whether there
is a problem in the first place. If implementation fails, costs are
incurred without appreciable benefits. Here, an in-depth analysis
of the extent and consequences of the perceived problem may be
at least as informative as evidence on the effectiveness of the pro-
posed solution.
Before early HTA can become standard practice, several chal-
lenges need to be addressed. First, at present, it is unclear who is
responsible for evaluating the potential value of a technology in
the early stages of its development and who should fund it. In
the view of the medical device industry, early value assessments
preferably are an integral part of research and development or mar-
keting process. However, HTA bodies, hospitals, and regulators
may all have different stakes in the systematic investigation of a
technology’s potential value, as well as different criteria for decision
making (e.g., profitability, quality of life, value for money). This
emphasizes the importance of early HTA being a joint effort of
the key stakeholders, with a clear and specific aim (17).
A second related and key challenge is the inclusion of patients
in the development and research of new technologies. Here,
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stakeholders can learn from initiatives like co-creation that are
gradually gaining ground in healthcare decision-making (18).
Third, the implementation of early HTA must be feasible and
fit in with the innovation process. It should not delay or stop the
development of technologies but rather create an environment in
which all parties can make informed decisions. This may then
result in the early discontinuation of technologies that do not
align with existing needs, while it will expedite the adoption of
valuable technologies. Ideally, this is an iterative process where
the design of research is informed and the assessment is updated
as more information becomes available, either about the technol-
ogy itself or the environment in which it would be used
(6;7;19;20).
Fourth, technology developers (in industry and hospitals)
often lack knowledge of early HTA, its use and usefulness, ham-
pering the implementation and advancement of the evaluation
method during the inception and early development of innova-
tions. Initiatives to update institutions to advance and guide
implementations of early HTA are recommended.
Fifth, most of the early HTA applications focus on the early
assessment of a new medical device, while it is also possible
and relevant to use early evaluations to determine the potential
of organizational or service innovations.
Sixth, by definition, early HTA is oriented toward the early
phases of technology development and, as such, needs to be
more nimble and flexible than traditional HTA. Arguably, intro-
ducing a different term for the approach may be helpful. One can
think of early value assessment or developmental value assess-
ment as these terms underscore that the goal of the evaluation
is not to assess the evidence on the technology but to explore
its potential value and guide evidence generation, which is why
there also is greater emphasis on qualitative methods than is cus-
tomary in conventional HTA (5). In early HTA it is not necessar-
ily the new technology but rather current care pathways that are
being assessed, where the leading questions should be: What tech-
nologies are currently available/applied? What benefits do they
offer? Where do they fall short? And what is the potential mar-
ginal value of the proposed technology?
The integration of early HTA in the innovation process may be
influenced by legislative developments. For example, the recent
legislative proposal to strengthen European Union cooperation
on HTA aims to make effective, innovative health tools available
to patients faster (21). However, this carries the risk that also
expensive yet low-value health technologies reach clinical practice
faster, thereby jeopardizing the sustainability of national health-
care systems. It is hence crucial that HTA is employed to prioritize
the most valuable innovations at the earliest stage possible, pref-
erably before or during its development.
Finally, under the new European Union Medical Device
Regulation, evidence generation will also need to be stepped up
(22;23), with the new legislature requiring early assessment meth-
ods that adequately address uncertainty and improve the effi-
ciency of research and development of innovations. By sharing
best practices and (experiences with) newly developed methodol-
ogies, all actors can profit.
In this commentary, five personal perspectives are presented,
highlighting similarities, all endorsed the importance of early
HTA to shape and refine an innovation, and inform research
and development decisions, but also differences. To advance the
field, we considered it valuable to share these perspectives, and
to search for the challenges that arise from these views. With
this we revealed important questions, such as who is responsible,
how can we develop nimble assessments, how can we make sure
all stakeholders are included? The next step would be to reach
consensus on these questions. To achieve this is, it is necessary
to create conditions in which learning among stakeholders is pos-
sible. Stakeholders have different views of what challenges we are
facing, what strategies are likely to work, and what is needed to
take the issue further. However, the underlying assumptions
remain implicit, and as such, are unavailable for critical scrutiny.
By making them explicit, stakeholders gain a better understanding
of their own position, but may also gain a better understanding in
how and where they differ from other stakeholders. Deliberative
methods, such as interactive interviews and focus groups, can
support this learning. Continuous action and reflection will be
necessary to evaluate the process of reaching consensus, in
order to really integrate early value assessment in the innovation
process.
Conclusion
In this commentary, the value and challenges of integrating early
HTA or early value assessments in the medical innovation process
are discussed from different perspectives. Representatives of five
key stakeholders largely agreed that it is more effective to steer
innovations in an early phase of their development rather than
having to modify or retract them in the final stages, or after
they have been introduced in clinical care, due to their having
insufficient or no added value. For early evaluations to be success-
ful, all relevant stakeholders, including patients, need to be
involved as early as possible. To become standard practice in
health innovation, methods need to allow for nimble and flexible
assessments that fit the dynamics of medical technology, while
experiences with their development and use need to be shared
to foster best practices and contribute to the optimization of
early value assessments.
Acknowledgements. When performing this study, Dr. Kværner received
funding from the Norwegian Research Council.
Conflicts of interest. Dr. Kvaerner reports grants from the Norwegian
Research Council, during the conduct of the study. Dr. Sampietro-Colom
reports grants from Fresenius and personal fees from Edwards Life Science,
outside the submitted work. Dr. Hamerlijnck reports financial activities
from NOVARTIS US, European Patient Forum, ZonMW, Zorginstituut
Netherlands, PGO support Netherlands, University Medical Centre Utrecht,
Dutch research Council, IMI patient group, and PHARMERIT, all outside
the submitted work. She is the patient co-chair of the European Respiratory
Society Clinical Research Consortium Severe Heterogeneous Asthma
Research Collaboration, Patient-centered and as such has received travel grants
for conferences and meetings. Dr. Siebert reports financial activities from
Abbott, outside the submitted work. The other authors declare no conflicts
of interest.
References
1. O’Rourke B, Oortwijn W, Schuller T, International Joint Task G. The
new definition of health technology assessment: A milestone in interna-
tional collaboration. Int J Technol Assess Health Care. 2020;36:187–190.
2. Lehoux P, Miller FA, Daudelin G, Denis JL. Providing value to new
health technology: The early contribution of entrepreneurs, investors,
and regulatory agencies. Int J Health Policy Manag. 2017;6:509–18.
3. Campbell B, Campbell M, Dobson L, Higgins J, Dillon B, Marlow M,
et al. Assessing the value of innovative medical devices and diagnostics:
The importance of clear and relevant claims of benefit. Int J Technol
Assess Health Care. 2018;34:419–24.
484 Marcia Tummers et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0266462320000756
Downloaded from https://www.cambridge.org/core. Erasmus MC Rotterdam, on 18 Feb 2021 at 13:10:39, subject to the Cambridge Core terms of use, available at
4. IJzerman MJ, Koffijberg H, Fenwick E, Krahn M. Emerging use of
early health technology assessment in medical product development:
A scoping review of the literature. Pharmacoeconomics. 2017;35:
727–40.
5. Stome LN, Moger T, Kidholm K, Kvaerner KJ. Early assessment of inno-
vation in a healthcare setting. Int J Technol Assess Health Care.
2019;35:17–26.
6. Sculpher M, Drummond M, Buxton M. The iterative use of economic
evaluation as part of the process of health technology assessment. J
Health Serv Res Policy. 1997;2:26–30.
7. Grutters JPC, Govers T, Nijboer J, Tummers M, van der Wilt GJ,
Rovers MM. Problems and promises of health technologies:
The role of early health economic modeling. Int J Health Policy.
2019;8:575–82.
8. Kluytmans A, Tummers M, Van der Wilt GJ, Grutters JPC. Early assess-
ment of proof-of-problem to guide health innovation. Value Health.
2019;22:601–6.
9. Girling A, Lilford R, Cole A, Young T. Headroom approach to device
development: Current and future directions. Int J Technol Assess Health
Care. 2015;31:331–8.
10. Frempong SN, Sutton AJ, Davenport C, Barton P. Economic evaluation
of medical tests at the early phases of development: A systematic review of
empirical studies. Expert Rev Pharm Out. 2018;18:13–23.
11. Abel L, Shinkins B, Smith A, Sutton AJ, Sagoo GS, Uchegbu I, et al.
Early economic evaluation of diagnostic technologies: Experiences of
the NIHR diagnostic evidence co-operatives. Med Decis Making. 2019;39:
857–66.
12. Markiewicz K, van Til JA, Steuten LMG, IJzerman MJ. Commercial via-
bility of medical devices using Headroom and return on investment calcu-
lation. Technol Forecast Soc. 2016;112:338–46.
13. Fasterholdt I, Krahn M, Kidholm K, Yderstraede KB, Pedersen KM.
Review of early assessment models of innovative medical technologies.
Health Policy. 2017;121:870–9.
14. Crespo C, Linhart M, Acosta J, Soto-Iglesias D, Martinez M, Jauregui
B, et al. Optimisation of cardiac resynchronisation therapy device selec-
tion guided by cardiac magnetic resonance imaging: Cost-effectiveness
analysis. Eur J Prev Cardiol. 2020;27:622–632.
15. Sampietro-Colom L, Martin J, editors. Hospital-based health technology
assessment: The next frontier for health technology assessment.
Switzerland: ADIS; 2016.
16. FDA. FDA Patient-Focused Drug Development Guidance Series for
Enhancing the Incorporation of the Patient’s Voice in Medical Product




17. Fasterholdt I, Lee A, Kidholm K, Yderstraede KB, Pedersen KM. A
qualitative exploration of early assessment of innovative medical technol-
ogies. BMC Health Serv Res. 2018;18:837.
18. Abrishami Shirazi P, Boer A, Horstman K. Value in co-creation:
Subjecting innovative in-hospital technologies to multi-stakeholder
appraisal. Int J Hosp Based Health Technol Assess. 2017;1(1):12–30.
19. Drummond MF. Modeling in early stages of technology development: Is
an iterative approach needed?; comment on “problems and promises of
health technologies: The role of early health economic modeling”. Int J
Health Policy. 2020;9:260–262.
20. Partington A, Karnon J. It’s not the model, it’s the way you use it:
Exploratory early health economics amid complexity; comment on “prob-
lems and promises of health technologies: The role of early health economic
modelling”. Int J Health Policy. 2020. doi: 10.15171/ijhpm.2020.04. Online
ahead of print.
21. European Commission. Assessing health technology in the EU:
Commission proposes to reinforce cooperation amongst Member States.
https://ec.europa.eu/commission/presscorner/detail/en/IP_18_4862018.
22. Official Journal of the European Union. Regulation (EU) 2017/745 of the
European Parliament and of the Council of 5 April 2017 on medical
devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002
and Regulation (EC) No 1223/2009 and repealing Council Directives 90/
385/EEC and 93/42/EEC. [cited 2019 March 5]; Available from: http://
eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2017.117.01.
0001.01.ENG&toc=OJ:L:2017:117:TOC.
23. Rothery C, Claxton K, Palmer S, Epstein D, Tarricone R, Sculpher M.
Characterising uncertainty in the assessment of medical devices and deter-
mining future research needs. Health Econ. 2017;26(Suppl 1):109–23.
International Journal of Technology Assessment in Health Care 485
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0266462320000756
Downloaded from https://www.cambridge.org/core. Erasmus MC Rotterdam, on 18 Feb 2021 at 13:10:39, subject to the Cambridge Core terms of use, available at
